RapidPulse is developing a pulsed (cyclic) aspiration platform and a range of catheter sizes intended to improve clot engagement, removal efficiency and procedural consistency during mechanical thrombectomy for acute ischemic stroke. The company’s system is being evaluated in the TURBO investigational device exemption study, conducted in the United States and Europe to support its U.S. regulatory pathway. RapidPulse plans to expand clinical experience with its system across leading stroke centers as part of that program and may pursue FDA approval if clinical data support a submission. The platform strategy includes continued development of the catheter portfolio and broader clinical use to gather performance data across different patients, clot types and treatment settings. RapidPulse was spun out of medical device incubator Syntheon and is headquartered in Miami. Financially, the company recently raised an oversubscribed $48 million Series B co-led by Medtronic, TechWald Next and S3 Ventures, with additional participation from SBI Investment Company, the Florida Opportunity Fund, and existing investors.

Total raised

$74M

Funding rounds

3

Latest round

Series B

Latest activity

Jul 2026